Global News

[ad_1] Hospitals face rising cases of respiratory illnesses - CBS News Watch CBS News Hospitals across the country are dealing with higher cases of COVID-19, the flu and RSV. The increase is being fueled in part by holiday travel and gatherings. Meg Oliver has the latest. Be the first to know Get browser notifications for breaking news, live events, and exclusive reporting. Not Now Turn On [ad_2] Source link https://worldnews2023.com/health/hospitals-face-rising-cases-of-respiratory-illnesses/?feed_id=318341&_unique_id=66f2f177270a6

[ad_1] It may still  feel like summer , but the fall is quickly approaching — along with the risk of seasonal viruses. On " CBS Mornings " Monday, Dr. Céline Gounder, a CBS News medical contributor and editor-at-large for public health at KFF Health News, shared what you need to know about protecting yourself from COVID-19 , the respiratory illness RSV and the flu — three infections that raised concerns last winter about the threat of a " tripledemic ." The recommendations are especially important for those at high risk, including people who are elderly, pregnant or have chronic health conditions. Here's what you need to know:  Is there an RSV vaccine? There are a few prevention tools for RSV, or respiratory syncytial virus , an illness that typically causes cold-like symptoms but can sometimes be severe, especially for infants and older adults. "(There's) a vaccine for the elderly for people 60 and up,

[ad_1] The Food and Drug Administration announced Monday it had approved a new kind of immunization to protect babies from RSV, or respiratory syncytial virus . The drug, nirsevimab, is one of two new options doctors hope could soon prevent the leading cause of hospitalization facing American infants. Outside advisers to the federal government have previously hailed nirsevimab's showing in clinical trials as potentially "groundbreaking" for protecting babies. A panel of the FDA's outside experts voted in June to back the drug's safety and efficacy. "Today's approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system," the FDA's Dr. John Farley, director of the Office of Infectious Diseases in the FDA's Center for Drug Evaluation and Research, said in a statement . Drugmakers AstraZeneca and Sanofi, which will market